FDA may require bispecific antibodies to be compared with monospecific products

With about 100 bispecific antibodies either in clinical trials or soon entering, the FDA on Monday updated and finalized its guidance on developing bispecific antibodies, clarifying how it may require clinical trials to compare the bispecifics with an approved monospecific product.

In the era of immunotherapies, the case for bispecifics...

Click to view original post